Squarepoint
DGX icon

Squarepoint’s Quest Diagnostics DGX Stock Holding History

Squarepoint’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,100
Closed -$1.75M – 4395
2025
Q4 		$1.75M Buy
+10,100
New +$1.84M ﹤0.01% 2157
2025
Q3 		– Sell
-2,300
Closed -$413K – 4483
2025
Q2 		$413K Sell
2,300
-43,400
-95% -$7.54M ﹤0.01% 3429
2025
Q1 		$7.73M Sell
45,700
-21,400
-32% -$3.52M 0.01% 1147
2024
Q4 		$10.1M Buy
67,100
+44,700
+200% +$6.95M 0.01% 1140
2024
Q3 		$3.48M Sell
22,400
-12,700
-36% -$1.9M 0.01% 1678
2024
Q2 		$4.8M Sell
35,100
-31,400
-47% -$4.3M 0.01% 1410
2024
Q1 		$8.85M Hold
66,500
– – 0.02% 1076
2023
Q4 		$9.17M Buy
66,500
+27,100
+69% +$3.56M 0.02% 998
2023
Q3 		$4.8M Buy
+39,400
New +$5.25M 0.01% 1207

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Squarepoint's DGX Position: Q1 2026 in Review

Squarepoint reduced its Quest Diagnostics (DGX) stake by 39% in Q1 2026, selling an estimated $42.7M and leaving 345,788 shares worth $67.8M. The position accounts for 0.08% of the portfolio, ranked #247.

Squarepoint first reported a position in DGX in Q2 2015 and has held it in 37 quarters since. The position peaked at $151M in Q2 2025. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Squarepoint held 345,788 shares of Quest Diagnostics worth $67.8M as of Q1 2026.
  • Squarepoint sold 220,012 Quest Diagnostics shares in Q1 2026, an estimated $42.7M.
  • Quest Diagnostics made up 0.08% of Squarepoint's portfolio in Q1 2026, its #247 holding.
  • Squarepoint first reported a position in Quest Diagnostics in Q2 2015 and has held it in 37 quarters since.
  • Squarepoint's Quest Diagnostics position peaked at $151M in Q2 2025.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.